Compare Heron Therapeutics Inc (HRTX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Yum! Brands, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Yum! Brands, Inc. trades at $149.01 (market cap $39.50B). The key difference: Yum! Brands, Inc. is far larger — about 642.6× Heron Therapeutics Inc's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | YUM | |
|---|---|---|
Market Cap | $61.47M | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $168.16 |
52-Week Low | $0.32 | $138.21 |
Enterprise Value | $168.21M | $51.10B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
YUM trades at $145.33, down 3.6% amid bearish technical signals and recent parasite outbreak concerns affecting Taco Bell sales. The company reported strong Q2 2026 earnings of $1.62 per share, beating estimates, with revenue growth continuing from $8.21B in 2025 to projected $8.7B in 2026. Valuation metrics show a P/E of 18.23 and P/S of 4.63, while debt reduction improved with debt-to-asset ratio declining to 143.49 in 2025.
The outlook remains mixed with analyst consensus price target of $174.60 suggesting 20% upside, but legal investigations and food safety issues pose near-term risks. Long-term growth drivers include digital expansion and portfolio optimization following Pizza Hut China sale, though execution on Taco Bell recovery is critical for sentiment improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
